Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2022 Earnings Conference Call July 28, 2022 5:00 PM ET

Company Participants

Joshua Higa - Executive Director & Head, Investor Relations

Emil Kakkis - Chief Executive Officer & President

Erik Harris - Chief Commercial Officer

Mardi Dier - Chief Financial Officer

Camille Bedrosian - Chief Medical Officer

Conference Call Participants

Gena Wang - Barclays

Joel Beatty - Baird

Dae Gon Ha - Stifel

Tazeen Ahmad - Bank of America

Cory Kasimov - JPMorgan

Yaron Werber - Cowen

Joon Lee - Truist

Liisa Bayko - Evercore ISI

Ashiq Mubarack - Citi

Operator

Good afternoon and welcome to the Ultragenyx Second Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. At the end of the prepared remarks, you will have the opportunity to ask the question during the Q&A portion of the call.

It is now my pleasure to turn today's call over to Joshua Higa, Executive Director and Head of Investor Relations.

Joshua Higa

Thank you. We issued a press release detailing our financial results, which you can find on our website at ultragenyx.com.

Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Mardi Dier, Chief Financial Officer; and Camille Bedrosian, Chief Medical Officer.

I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.

I'll now turn the call over to Emil.

Emil Kakkis

Thanks Josh and good afternoon, everyone. We're now six months into the year. And across the company, we continue to make meaningful progress against our goals. The commercial team delivered another solid quarter of revenue growth as they commercialize their products across the globe. We acquired the late-stage product UX111 from MPS III or MPS IIIA or Sanfilippo Syndrome and MPS disease area for, which we have extensive experience.

In July, we bolstered our cash position with a substantial royalty financing that also enabled us to acquire genetics and gain full control of our important Angelman program. These activities along with progress across all of our early and late-stage clinical programs put us in good strong position over the coming years for exceptional value creation.

I want to touch on a couple of pipeline updates before turning the call over to the other leadership team members to provide more detail on the quarter. Starting with GTX-102 for Angelman syndrome, we reached a similar moment in this program with the acquisition of Genetics and now a full control over the GTX-102 program.